deferoxamine mesylate

de·fer·ox·a·mine mes·y·late

(de'fĕr-ok'să-mēn mes'i-lāt),
Chelate used to treat iron poisoning; also chelates aluminum.

deferoxamine mesylate

[dē′fərok′səmēn]
a chelating agent with specific affinity for ferric iron and low affinity for calcium.
indications It is prescribed in the treatment of acute iron intoxication and chronic iron overload.
contraindications Renal disease or anuria prohibits its use.
adverse effects Among the most serious adverse reactions are hypotension, tachycardia, dysuria, visual difficulties, and anaphylactoid reactions.

deferoxamine mesylate

(dĕ-fĕr-ŏks′ă-mēn)
A drug with a very high affinity for iron. It is used parenterally to reduce the iron overload in patients with hemochromatosis, acute iron poisoning, or multiple blood transfusions.
References in periodicals archive ?
In treatment group 3, birds were treated with deferoxamine mesylate (100 mg/kg SC q24h; Desferal, Novartis Pharmaceuticals Corp, East Hanover, N J, USA) in addition to the low-iron diet.
The chief problem with deferoxamine mesylate therapy is that patients sometimes skip treatments, notes Stanley L.
Researchers in Italy compared deferoxamine mesylate with ICL670 in 71 patients with an average age of 25.
Periodic testing of iron content in the patients' blood and liver over a year showed that ICL670 cleared transfusion-caused iron overload as well as deferoxamine mesylate did, says study coauthor Antonio Piga of Turin University.